Revolutionizing Colorectal Cancer Screening

High-precision blood-based testing for early detection of colorectal cancer. Reproducible, affordable, and reliable at all stages of the disease

Colorectal Cancer,
CRC

3 - 2 - 1

Third most common¹ cancer disease globally and the second most deadly².
The most deadly cancer type for people under 50³

¹IARC 2022; ²WHO 2023; ³JAMA 2026; ⁴RKI, ZfKD 2024

of CRC patients suffer and die within less than 10 years⁴

Screening participation is still low.
Globally, only 1 of 3 persons eligible to get screened participates and often CRC is detected too late

Why
CRC Screening?

Early Detection
of Colorectal
Cancer

Early-stage CRC has a much higher survival rate compared to late-stage disease

Prevention
through
Polyp Removal

Screening can detect precancerous polyps (adenomas)

Reduces
Treatment Cost

Early detection can reduce treatment cost by 0x

Why Choose
hematIQ for Screening?

Our innovative approach to colorectal cancer screening addresses the limitations of traditional methods

Early Detection

Detect colorectal cancer and precancerous lesions at early stages when treatment is most effective

High Precision

Validated assay with exceptional precision in analysis and processes, backed by renowned institutions

Non-Invasive

Simple blood test requiring only 1μl plasma sample - no invasive procedures or uncomfortable preparations

The Science Behind Our Innovation

Our non-invasive blood test identifies a specific panel of tumor-related proteins to detect early-stage colorectal cancer and precancerous lesions with unprecedented accuracy

Validated by Leading Institutions

Approved and analyzed by Sahlgrenska Hospital & Gothenburg University

100% Accuracy

No single sample was mis-classified in our validation studies

Existing Infrastructure

Works with existing laboratory workflows and equipment

Intellectual Property

Patent applied and granted

Addressing Market Challenges

Traditional screening methods face significant barriers
Our solution provides the answers

Current Problems

Low participation rates (4-78%)

Invasive and unpleasant procedures

Late detection leads to high mortality

High false positive rates provoke cost and risk

High false negative rates fail to find cancer

Our Solutions

Test can be made from routine check-up sample

No dietary preparation, no invasive procedure

Validated precision and accuracy

Reduced need for colonoscopies

Highly Skilled Team

We are a highly experienced team with diverse background and expertise. Medicine, Quality, Regulatory, Science, Finance, Analytics, Statistics, Marketing – lots of synergies, no redundancies

World-Class Advisors

Our Advisors complement the expertise of our team. We gladly rely in the knowledge reaching from cancer science via entrepreneurial set and launching a new diagnostic up to heading global sales of a DAX100 company

Get in Touch

Ready to learn more about our revolutionary diagnostic technology?

Contact Information

General Inquiries

info@hematiq.com

Investor Inquiries

hartwiegl@hematiq.com

Address

hematIQ AB
GoCo House, Entreprenörssträket 10
431 53 Mölndal, Sweden